for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ironwood Pharmaceuticals, Inc.

IRWD.OQ

Latest Trade

10.20USD

Change

0.00(-0.00%)

Volume

873,528

Today's Range

10.03

 - 

10.34

52 Week Range

7.92

 - 

14.10

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
10.20
Open
10.09
Volume
873,528
3M AVG Volume
47.53
Today's High
10.34
Today's Low
10.03
52 Week High
14.10
52 Week Low
7.92
Shares Out (MIL)
159.98
Market Cap (MIL)
1,625.66
Forward P/E
23.83
Dividend (Yield %)
--

Next Event

Q3 2020 Ironwood Pharmaceuticals Inc Earnings Release

Latest Developments

More

Ironwood Pharmaceuticals Qtrly SHR from Cont Ops $0.16

Ironwood Posts Quarterly Income From Continuing Operations Per Share $0.16

Ironwood Announces Updates Designed To Strengthen Iw-3718 Phase 3 Program For Refractory Gastroesophageal Reflux Disease

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).

Industry

Biotechnology & Drugs

Contact Info

100 Summer St Ste 2300

BOSTON, MA

02110-2156

United States

+1.617.6217722

http://www.ironwoodpharma.com/

Executive Leadership

Julie H. McHugh

Independent Chairman of the Board

Thomas A. McCourt

President

Mark Mallon

Chief Executive Officer, Director

Gina Consylman

Chief Financial Officer, Senior Vice President

Jason Rickard

Chief Operating Officer, Senior Vice President

Key Stats

2.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.3K

2018

0.3K

2019

0.4K

2020(E)

0.4K
EPS (USD)

2017

-0.930

2018

-0.950

2019

0.550

2020(E)

0.448
Price To Earnings (TTM)
16.57
Price To Sales (TTM)
3.81
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
15.87
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
31.22
Return on Equity (TTM)
25.57

Latest News

Latest News

BRIEF-Ironwood, Abbvie Report MD-7246 Phase 2 Data In Patients With Abdominal Pain Associated With IBS-D

* IRONWOOD AND ABBVIE REPORT TOP-LINE PHASE II DATA FOR MD-7246 IN PATIENTS WITH ABDOMINAL PAIN ASSOCIATED WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D)

BRIEF-Ironwood, Allergan Receive Notices Of Allowance For Patent Applications Covering 72 MCG Dose Of Linzess

* IRONWOOD AND ALLERGAN RECEIVE NOTICES OF ALLOWANCE FOR PATENT APPLICATIONS COVERING 72 MCG DOSE OF LINZESS® (LINACLOTIDE)

BRIEF-Ironwood Pharmaceuticals Provides Update On Impact Of COVID-19

* IRONWOOD PHARMACEUTICALS PROVIDES UPDATE ON IMPACT OF COVID-19

BRIEF-Ironwood Pharma Says Suspending Interactions By Customer-Facing Employees Through March

* IRONWOOD PHARMACEUTICALS - SUSPENDING PERSONAL INTERACTIONS BY CUSTOMER-FACING EMPLOYEES THROUGH AT LEAST MARCH 31 Source text: (https://bit.ly/2xHKXFP) Further company coverage:

BRIEF-Ironwood Pharmaceuticals Announces Publication Of Positive Iw-3718 Phase Iib Data In Gastroenterology

* IRONWOOD PHARMACEUTICALS ANNOUNCES PUBLICATION OF POSITIVE IW-3718 PHASE IIB DATA IN GASTROENTEROLOGY Source text for Eikon: Further company coverage:

BRIEF-Ironwood Pharmaceuticals Reports Q4 EPS Of $0.30

* IRONWOOD PHARMACEUTICALS REPORTS STRONG FOURTH QUARTER AND FULL YEAR 2019 RESULTS, EXCEEDING FULL YEAR 2019 GUIDANCE; PROVIDES FULL YEAR 2020 GUIDANCE

BRIEF-Ironwood, Allergan Announce Settlement Resolving Linzess (Linaclotide) Patent Litigation

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION

BRIEF-Ironwood Pharma Sends Letter To Shareholders Highlighting Director Nominees

* IRONWOOD PHARMACEUTICALS SENDS LETTER TO SHAREHOLDERS HIGHLIGHTING DIRECTOR NOMINEES

BRIEF-Ironwood And Allergan Announce Settlement With Aurobindo Pharma Resolving Linzess Patent Litigation

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH AUROBINDO PHARMA RESOLVING LINZESS (LINACLOTIDE) PATENT LITIGATION

BRIEF-Ironwood Pharmaceuticals To Separate Into Two Independent, Publicly Traded Companies

* IRONWOOD PHARMACEUTICALS ANNOUNCES INTENT TO SEPARATE SOLUBLE GUANYLATE CYCLASE (SGC) BUSINESS FROM COMMERCIAL AND GASTROINTESTINAL BUSINESS

BRIEF-Ironwood Pharmaceuticals Reports Q1 Loss Per Share Of $0.29

* IRONWOOD PHARMACEUTICALS PROVIDES FIRST QUARTER 2018 INVESTOR UPDATE

BRIEF-Ironwood Announces Director Nomination From Sarissa Capital

* RECEIVED NOTICE FROM SARISSA CAPITAL MANAGEMENT LP OF INTENTION TO NOMINATE ALEX DENNER TO STAND FOR ELECTION Source text for Eikon: Further company coverage:

BRIEF-Ironwood Pharmaceuticals Qtrly GAAP Net Income Per Share $0.08

* EXPECTS TO USE LESS THAN $75 MILLION IN CASH FOR OPERATIONS IN 2018 Source text for Eikon: Further company coverage:

BRIEF-Ironwood Pharmaceuticals Implements Reduction In Field-Based Workforce

* SAYS COMMENCED AN INITIATIVE TO EVALUATE OPTIMAL MIX OF INVESTMENTS FOR LESINURAD FRANCHISE FOR UNCONTROLLED GOUT

BRIEF-Allergan, Ironwood Announce Settlement With Sun Pharma

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION

BRIEF-Ironwood Pharmaceuticals Sees U.S. Net Sales Of Linzess Of About $700 Million For FY Ended Dec 31, 2017

* IRONWOOD PHARMACEUTICALS INC - EXPECTED U.S. NET SALES OF LINZESS (LINACLOTIDE) OF ABOUT $700 MILLION FOR FY ENDED DEC 31, 2017

BRIEF-Ironwood Reports Top-Line Phase IIa Data For IW-1973

* IRONWOOD REPORTS TOP-LINE PHASE IIA DATA FOR IW-1973 DEMONSTRATING POSITIVE CARDIOVASCULAR, METABOLIC AND ENDOTHELIAL EFFECTS

BRIEF-Ironwood Pharmaceuticals Strengthens Executive Leadership Team

* IRONWOOD PHARMACEUTICALS STRENGTHENS EXECUTIVE LEADERSHIP TEAM

BRIEF-Ironwood Pharma files for potential mixed shelf offering

* Ironwood Pharmaceuticals Inc files for potential mixed shelf offering; size not disclosed - SEC filing Source text: (http://bit.ly/2h08KF7) Further company coverage:

BRIEF-Ironwood Pharmaceuticals Q3 non-GAAP loss per share $0.18

* Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up